Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

April 25, 2024

https://www.globenewswire.com/news-release/2024/04/25/2870049/0/en/Aligos-Therapeutics-Presents-Positive-Clinical-Data-at-ESCMID-2024-from-the-ALG-097558-Phase-1-Study.html

Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting

SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq:ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced an ePoster flash session presentation at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2024, being held April 27-30, 2024 in Barcelona, Spain.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.